Combined Let-7a and H19 Signature: A Prognostic Index of Progression-Free Survival in Primary Breast Cancer Patients

Qiannan Guo1,2,*, Runyao Wen1,2,*, Bin Shao3, Yudong Li1,2, Xin Jin1,2, Heran Deng1,2, Jiannan Wu1,2, Fengxi Su1,2, Fengyan Yu1,2

1Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation and 2Department of Breast Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou; 3Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Peking, China

Purpose: The long non-coding RNA H19, a conservatively imprinted gene, acts as a molecular sponge for the let-7 family, which has been identified as a set of tumor suppressors. However, the combined prognostic value of H19 and let-7a signature in breast cancer patients remains unclear. Methods: In this research we assessed the prognostic value of the combined H19 and let-7a signature in breast cancer patients by retrospectively reviewing that data of 79 patients who underwent neoadjuvant chemotherapy; we also investigated the expression and function of H19 in breast cancer cell lines in vitro. Survival data were calculated using the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate survival analyses were conducted using the Cox proportional hazards regression method. As determined using X-tile, the optimal cutoff value for the risk score to assess progression-free survival (PFS) based on the combined signature was ~0.1. Results: Patients with an overall positive treatment response had higher let-7a and lower H19 levels. In addition, let-7a expression was negatively correlated with H19 expression. Patients with a risk score of >-0.1 had shorter overall survival and PFS. In vitro data showed that chemoresistant cell lines exhibit higher H19 and lower let-7a levels and knockdown H19 restores paclitaxel sensitivity. Conclusion: Our results suggest that the combined let-7a and H19 signature is a novel prognostic factor for breast cancer patients treated with neoadjuvant chemotherapy.

Key Words: Breast neoplasms, H19 long non-coding RNA, Hsa-let-7a-1 microRNA, Neoadjuvant therapy, Prognosis

INTRODUCTION

Globally, breast cancer is one of the most frequently diagnosed cancers, and it is responsible for most cancer-related deaths in women [1]. Many patients initially present with disease at late stages because they do not have any obvious symp-

Correspondence to: Fengyan Yu
Department of Breast Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiang West Road, Guangzhou 510120, China
Tel: +86-20-34071287, Fax: +86-20-34070091
E-mail: fengyan_yu_summer@163.com

*These authors contributed equally to this work.
This work was supported by grants from Natural Science Foundation of China (81472731), Guangdong Natural Science Funds for Distinguished Young Scholar (201500111199), Beijing Natural Science Foundation (2162044), and grants from Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology (Grant [2013]163), from the Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes (KL.809001), and from Guangdong Science and Technology Department (2015B050501004).

Received: December 15, 2017 Accepted: May 25, 2018

© 2018 Korean Breast Cancer Society. All rights reserved.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
miRNA-675 could downregulate proto-oncogene proteins and casitas b-lineage lymphoma b, which may strengthen the tumorigenesis and metastasis of breast cancer cells. Moreover, in estrogen receptor α-positive breast cancer, H19 confers chemoresistance by silencing the pro-apoptotic gene BCL2 interacting killer [7]. Furthermore, Peng et al. [8] found that H19 could sponge let-7 by acting as a competing endogenous RNA and upregulate the expression of the core pluripotency factor LIN28, a let-7 target. Additionally, H19, let-7, and transcriptional factor LIN28 form a double-negative feedback loop which is of great importance in the maintenance of breast cancer stem cells [8]. Recently, Kallen et al. [9] also reported that H19 acts IncRNAs act as a molecular sponge for the let-7 family of miRNAs. Our previous study using clinical samples and in vitro cell lines demonstrated that in breast cancer tumor tissues, low expression of let-7a is related to epirubicin resistance [10]. Considering these findings, we hypothesized that the combination of let-7 and H19 has a prognostic value in predicting chemotherapy response and disease outcomes in breast cancer.

Thus, we conducted a retrospective cohort study to examine the prognostic value of the combined H19 and let-7a signature in predicting the chemotherapy response and prognosis of breast cancer patients who received epirubicin-based neoadjuvant chemotherapy. Additionally, we investigated the expression levels and the functions of H19 in breast cancer cell lines in vitro.

METHODS

Patients selection and evaluation

We performed quantitative real-time polymerase chain reaction (qRT-PCR) on tissues from 79 breast cancer patients’ snap-frozen core needle biopsies taken before any treatment at the Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University between January 2013 and December 2014. Each case was pathologically confirmed as invasive ductal breast cancer, and epirubicin plus cyclophosphamide every 3 weeks for four cycles (EC) or EC followed by weekly paclitaxel for 12 weeks was administered, and trastuzumab was combined with chemotherapy for her-2 positive cases based on the National Comprehensive Cancer Network (NCCN) guidelines. This study was approved by the Ethics Committee of Sun Yat-sen Memorial Hospital (2016-SYS-KY-LB-118). All participants provided written informed consent. Each procedure of this study was in accordance with the ethical standards set by the institutional research committee and the 1964 Helsinki Declaration and its amendments. All patients underwent breast surgery 1 month after the last neoadjuvant chemotherapy. We evaluated the clinical chemotherapeutic response by measuring the tumor size before and after treatment based on the Response Evaluation Criteria in Solid Tumors (version 1.1). Responses were categorized as follows: (a) complete response (CR), the disappearance of all known diseases; (b) partial response (PR), tumor size decreased by more than 30.0%; (c) stable disease (SD), tumor size increased by less than 20.0% or decreased by less than 30.0%; and (d) progressive disease (PD), new lesions appeared or tumor size increased by more than 20.0%. In this study, we defined CR and PR as responders and SD and PD as nonresponders. The subsequent treatment after surgery was conducted according to the NCCN guidelines.

RNA isolation and qRT-PCR assay

We used TRIzol (Invitrogen, Carlsbad, USA) and the RNeasy mini kit (Qiagen, Valencia, USA) to extract the total RNA from snap-frozen core needle biopsies of breast cancer patients according to the manufacturer’s instructions. The expression levels of let-7a and H19 were detected using qRT-PCR using TaqMan Universal PCR master mix (Applied Biosystems Inc., Foster City, USA) according to the manufacturer’s instructions. We used the TaqMan Reverse Transcription Kit (Applied Biosystems Inc.) to reverse transcribe each sample into a total of 1 µg of RNA. Each PCR amplification was performed in a final volume of 10 µL using the CFX384 Real-Time PCR Detection System (Bio-Rad, Hercules, USA). Amplifications were initiated via denaturation for 10 minutes at 95°C followed by 40 cycles at 95°C for 15 seconds and 60°C for 60 seconds. Each reaction was performed in triplicate. U6 RNA and glyceraldehyde-3-phosphate dehydrogenase RNA was used as respective internal controls to normalize the expression levels of miRNA and IncRNA. The data were analyzed by using the comparative cycle threshold method, and the fold difference in expression was normalized against the sample with the lowest expression level.

Cell culture and treatment

We obtained the MDA-MB-231 cell line from the American Type Culture Collection and cultured the cells in RPMI-1640 medium supplemented with 10.0% fetal bovine serum (FBS). A paclitaxel-resistant MDA-MB-231 cell line (MDA-MB-231p) was maintained in RPMI-1640 medium without phenol red (Life Technologies, Carlsbad, USA) supplemented with 5.0% charcoal-stripped FBS (HyClone, Logan, USA) and 50 nM paclitaxel. Cell transfection with miRNA mimics (GenePharma, Shanghai, China) was performed by using Lipofectamine (Invitrogen) as previously described [10].
Cell viability and apoptosis

A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to measure cell viability. In brief, the cells were plated in triplicate at a density of 15,000 cells per well in a 96-well plate and incubated for 24 hours at 37°C, after which various concentrations of paclitaxel were added and the plates were incubated for a further 48 hours. Cell viability was assayed by adding 0.1 mg/mL MTT solution, incubating the plates for 3 hours, and measuring the absorbance at 490 nm using a 96-well plate reader. Flow cytometry was used to measure cell apoptosis. In brief, the cells were treated with paclitaxel for 24 hours, collected, and then washed twice. A total of 1 × 10⁶ cells were diluted with 500 µL of 1 × assay buffer, followed by the addition of 5 µL Annexin V-fluorescein isothiocyanate (FITC) and 10 µL propidium iodide (PI). After a 5-minute incubation period, we immediately analyzed the samples on a Beckman Coulter EPICS-XL MCL flow cytometer (Beckman Coulter Inc., Brea, USA). The fluorescence of FITC and PI was detected using 530 nM and 585 nM bandpass filters, respectively. Approximately 10,000 cells were collected for each sample. All these tests were performed in triplicate.

Statistical analysis

We defined overall survival (OS) as the time from initial diagnosis to the time of death related to any cause or to the time of the most recent follow-up. We defined progression-free survival (PFS) as the time from initial diagnosis to the time of the first sign of disease progression or death from any cause. Our final follow-up was on December 31, 2016. We assessed the relationship between the clinical characteristics and either miRNA or lncRNA expression using Student t-test, chi-square test, or Fisher exact test, as appropriate. To further assess let-7a and H19, a risk score formula was developed based on a linear combination of the let-7a and H19 expression levels weighted by the regression coefficient derived from the univariate Cox regression analysis. In addition, a bioinformatics tool, X-tile [11], was used to determine the cutoff value for let-7a, H19, and the risk score. We used the Kaplan-Meier method and log-rank test to estimate OS and PFS, and we calculated hazard ratios (HRs) by using an adjusted multivariate Cox regression analysis. To identify whether the expression of let-7a and H19 was associated with OS and PFS, we conducted univariate Cox regression analysis and identified significant differences (p < 0.05) in let-7a and H19 expressions. We constructed a signature that contains these two indices using the risk score method and analyzed its significance as an indicator of survival outcomes. Later, we conducted multivariate Cox regression analysis by using a forward stepwise approach to test whether let-7a, H19, or their combined signature was an independent prognostic factor for OS and PFS. H19 expression, let-7a expression, and treatment response were considered as covariates. Receiver operating characteristic (ROC) curves were applied to compare the specificity and sensitivity of let-7a, H19, and the combined signature for the prediction of survival. All statistical analyses were conducted by using SPSS version 20.0 (IBM, Armonk, USA) with two-tailed tests, and significance was defined as a p-value of < 0.05.

RESULTS

Neoadjuvant chemotherapeutic resistance and levels of let-7a and H19

To study the relationship between the expression levels of let-7a and H19 and the chemotherapy response, we detected the expression levels of RNA via qRT-PCR using fresh frozen
breast cancer tissues from 79 patients who received epirubicin-based neoadjuvant chemotherapy. Among the 79 patients, CR and PR were achieved by seven and 40 patients, respectively, while SD and PD were achieved by 29 and three patients, respectively. In the responders, the average relative expression levels of let-7a and H19 were 11.30 (range, 1.74–16.88) and 6.34 (range, 1.20–13.45), respectively, while in the nonresponders, they were 4.49 (range, 0.66–14.54) and 12.42 (range, 1.24–18.00), respectively. Consistent with our previous study, we observed that lower let-7a levels were associated with an inferior treatment response \( (p < 0.001) \). We also identified that the nonresponders had higher \( H19 \) expression levels \( (p < 0.001) \) (Figure 1A and 1B). In addition, Pearson \( r \) correlation analyses indicated that \( let-7a \) expression was negatively associated with \( H19 \) expression \( (r = -0.566, p < 0.001) \) (Figure 1C).

**\( H19 \) is associated with drug-resistance in breast cancer cells**

Our previous study reported the restoration of chemosensitivity after inducing \( let-7a \) expression \( [10] \). Thus, in this study, we primarily focused on the function of \( H19 \). We compared the \( H19 \) expression levels in MDA-MB-231 and MDA-MB-231p cell lines using qRT-PCR. We observed that MDA-MB-231 cells rarely expressed \( H19 \), while the mean expression level of \( H19 \) in the paclitaxel-resistant cells was 13.04-fold higher than in the non-resistant MDA-MB-231 cell line \( (p = 0.002) \) (Figure 2A).

To determine whether changes in \( H19 \) expression impact the drug response, we knocked down \( H19 \) using small interfering RNA (siRNA) and measured drug sensitivity using the MTT assay. The half maximal inhibitory concentration (IC\(_{50}\)) values of paclitaxel in the MDA-MB-231 cell line and the paclitaxel-resistant cell line were 53.83 ± 4.16 nM and 372.20 ± 59.81 nM, respectively. After knockdown of \( H19 \) in MDA-MB-231p cells with siRNA-1 or siRNA-2, the IC\(_{50}\) values were 74.44 ± 8.40 nM \( (p = 0.008) \) and 65.45 ± 6.44 nM \( (p = 0.007) \), respectively. These data suggest that siRNA-mediated knockdown of \( H19 \) in both drug-resistant cell lines restored sensitivity to paclitaxel (Figure 2B).

Next, we explored whether the observed drug resistance was associated with impaired apoptosis. Based on the exter-
nalization of phosphatidylserine as a known hallmark of apoptosis, we conducted flow cytometric analyses of cells treated with Annexin V-FITC to detect the levels of drug-induced apoptosis in these cell lines. After 24 hours of paclitaxel treatment, the apoptosis rate of MDA-MB-231p cells was only 3.5% ± 0.9%. However, the two siRNA-transfected cell lines exhibited apoptosis rates of 13.8% ± 1.5% ($p = 0.004$) and 18.2% ± 1.6% ($p = 0.001$). Therefore, these results may indicate that $H19$ regulates drug resistance by impairing apoptosis (Figure 2C).

**$H19$ and let-7a have prognostic value in breast cancer patients treated with neoadjuvant chemotherapy**

To investigate the long-term prognostic value of let-7a and $H19$, we analyzed the patients’ follow-up data and found that let-7a and $H19$ levels were associated with OS and PFS. Thus, we derived a formula to calculate the risk score for each patient based on the expression levels of let-7a and $H19$ weighted by regression coefficients as follows:

$$\text{Risk score} = (-0.126 \times \text{expression level of let-7a}) + (0.115 \times \text{expression level of } H19)$$

Using the biostatistical tool X-tile, we set –0.1 as the optimal cutoff level for the risk score to assess survival. Thus, the cohort was divided into high-risk ($> –0.1, n = 32$) and low-risk ($\leq –0.1, n = 47$) groups according to the risk score. These two groups’ clinicopathological characteristics are listed in Table 1. The clinical characteristics, including age, estrogen receptor, progesterone receptor, human epidermal growth factor recep-

### Table 1. Demographic and baseline characteristics of 79 primary breast cancer patients

| Characteristic                      | No. (%)     | Low risk group ($\leq –0.1$) No. (%) | High risk group ($> –0.1$) No. (%) | $p$-value |
|-------------------------------------|-------------|--------------------------------------|------------------------------------|-----------|
| Age (yr)*                           | 49 (24–73)  | 46 (24–70)                            | 50.5 (31–73)                       | 0.978     |
| estrogen receptor                   | 56 (70.9)   | 34 (72.3)                             | 22 (68.7)                          | 0.108     |
| Positive                            | 3 (6.4)     | 31 (66.0)                             | 15 (46.9)                          | 0.819     |
| Negative                            | 3 (6.4)     | 16 (34.0)                             | 17 (53.1)                          | 0.118     |
| progesterone receptor               | 58 (73.4)   | 38 (83.9)                             | 29 (62.5)                          |           |
| HER2                                | 21 (26.6)   | 9 (19.1)                              | 12 (37.5)                          |           |
| positive                            | 3 (6.2)     | 2 (4.3)                               | 6 (18.8)                           | 0.129     |
| HER2                                | 45 (57.0)   | 29 (61.7)                             | 16 (32.7)                          |           |
| Ki-67 (%)                           | 21 (26.6)   | 14 (29.8)                             | 7 (21.9)                           | 0.142     |
| miRNA let-7 ΔCt*                    | 9.68 (1.00–17.00) | 11.53 (1.74–16.88) | 4.68 (0.66–14.54) | <0.001 |
| IncRNA H19 ΔCt*                     | 7.92 (1.20–18.00) | 6.30 (1.20–8.32) | 12.70 (8.41–18.00) | <0.001 |
| T stage                             |             |                                      |                                    |           |
| T1                                  | 3 (3.8)     | 2 (2.1)                               | 6 (2.2)                            |           |
| T2                                  | 47 (59.5)   | 31 (66.0)                             | 16 (32.7)                          |           |
| T3                                  | 21 (26.6)   | 13 (27.7)                             | 6 (18.8)                           |           |
| T4                                  | 8 (10.1)    | 2 (4.3)                               | 6 (18.8)                           |           |
| N stage                             |             |                                      |                                    |           |
| N0                                  | 21 (26.6)   | 14 (29.8)                             | 7 (21.9)                           | 0.086     |
| N1                                  | 45 (57.0)   | 29 (61.7)                             | 16 (32.7)                          |           |
| N2                                  | 9 (11.4)    | 3 (6.4)                               | 6 (18.8)                           |           |
| N3                                  | 4 (5.1)     | 1 (2.1)                               | 3 (9.4)                            |           |
| stage                               |             |                                      |                                    |           |
| I                                   | 1 (1.3)     | 1 (2.1)                               | 1 (2.1)                            | 0.710     |
| II                                  | 47 (59.5)   | 32 (68.1)                             | 15 (46.9)                          |           |
| III                                 | 23 (29.1)   | 12 (25.5)                             | 11 (34.4)                          |           |
| IV                                  | 8 (10.1)    | 2 (4.3)                               | 6 (18.8)                           |           |
| Chemotherapy regimen                |             |                                      |                                    |           |
| EC                                  | 6 (7.6)     | 4 (8.5)                               | 2 (6.2)                            |           |
| EC-P                                | 73 (92.4)   | 43 (91.5)                             | 30 (93.8)                          |           |
| Treatment response                  |             |                                      |                                    | <0.001    |
| CR+PR                               | 47 (59.5)   | 42 (89.4)                             | 5 (15.6)                           |           |
| PD+SD                               | 32 (40.5)   | 5 (10.6)                              | 27 (84.4)                          |           |

HER2 = human epidermal growth factor receptor 2; miRNA = microRNA; IncRNA = long non-coding RNA; ΔCt = comparative cycle threshold; EC = epirubicin and cyclophosphamide; EC-P = epirubicin, cyclophosphamide followed by paclitaxel; CR = complete response; PR = partial response; PD = progressive disease; SD = stable disease.

*Median (range); †Mean ± standard deviation.
tor 2 (HER2), Ki-67, and stage, and chemotherapy regimens were comparable between the two groups. The median follow-up period of the entire cohort was 18 months (range, 4–32 months). At the time of the final follow-up, 25 patients suffered from disease relapse. We found that a risk score < –0.1 was significantly associated with a higher overall response rate (89.4% vs. 15.6%, p < 0.001). The median OS and PFS in the high-risk group were 16 months (range, 4–29 months) and 14 months (range, 4–24 months), respectively, whereas the median OS and PFS in the low-risk group were 20 months (range, 7–32 months) and 18 months (range, 7–32 months), respectively (Figure 3A).

We also used X-tile to determine the cutoff values for H19 and let-7a; both were included in the multivariate model as dichotomized variables. The cutoff values for these two indices were 7.10 and 11.30, respectively. The average values of H19 and let-7a were 5.99 ± 0.33 and 11.54 ± 0.44 (p < 0.001), respectively, in the low-risk group and 12.35 ± 0.62 and 4.64 ± 0.40 (p < 0.001), respectively, in the high-risk group.

Based on the univariate analysis, the risk score, the expression levels of let-7a and H19, and the treatment response were significant predictors of PFS (Table 2), but only the risk score and the treatment response were significant predictors of OS (Table 3). A risk score > –0.1 was associated with significantly inferior survival (PFS: HR, 0.221, 95% confidence interval [CI], 0.094–0.518, p = 0.001; OS: HR, 0.126, 95% CI, 0.020–0.806, p = 0.029). Neither tumor stage nor chemotherapy regimen displayed a significant prognostic impact. In the multivariate analysis, a risk score > –0.1 was observed to be an independent predictor of both PFS and OS (PFS: HR, 0.130, 95% CI, 0.084–0.480, p = 0.001; OS: HR, 0.090, 95% CI, 0.010–0.844, p = 0.035).

### Table 2. Univariate and multivariate analyses of the prognostic factors of progression-free survival for primary breast cancer patients

| Variable                        | Univariate |              |          |          | Multivariate |              |          |          |
|---------------------------------|------------|--------------|----------|----------|--------------|--------------|----------|----------|
|                                 |            | p-value      | HR (95% CI) |          | HR (95% CI) |              |          |          |
| Age (yr)                        | 0.809      | 0.905 (0.401–2.041) |          |          |              |              |          |          |
| Estrogen receptor               | 0.889      | 0.944 (0.423–2.109) |          |          |              |              |          |          |
| Progesterone receptor           | 0.872      | 1.075 (0.445–2.597) |          |          |              |              |          |          |
| HER2                            | 0.301      | 0.815 (0.553–1.201) |          |          |              |              |          |          |
| miRNA let-7                     | 0.019      | 3.031 (1.198–7.670) | 0.210    | 0.528 (0.195–1.432) |          |          |          |
| lncRNA H19                      | 0.014      | 0.346 (0.141–0.848) | 0.788    | 0.803 (0.162–3.985) |          |          |          |
| Risk score                      | 0.001      | 0.221 (0.094–0.518) | 0.001    | 0.130 (0.084–0.480) |          |          |          |
| T stage                         | 0.322      | 1.294 (0.777–2.153) |          |          |              |              |          |          |
| N stage                         | 0.697      | 0.883 (0.472–1.652) |          |          |              |              |          |          |
| Stage                           | 0.057      | 1.669 (0.985–2.829) |          |          |              |              |          |          |
| Chemotherapy regimen (EC/EC-P)  | 0.854      | 1.146 (0.268–4.904) |          |          |              |              |          |          |
| Treatment response (CR+PR/PD+SD)| 0.005      | 0.299 (0.130–0.691) | 0.508    | 1.478 (0.465–4.693) |          |          |          |

HR = hazard ratio; CI = confidence interval; HER2 = human epidermal growth factor receptor 2; miRNA = microRNA; lncRNA = long non-coding RNA; EC = epirubicin and cyclophosphamide; EC-P = epirubicin, cyclophosphamide followed by paclitaxel; CR = complete response; PR = partial response; PD = progressive disease; SD = stable disease.

### Table 3. Univariate and multivariate analyses of the prognostic factors of overall survival for primary breast cancer patients

| Variable                        | Univariate |              |          |          | Multivariate |              |          |          |
|---------------------------------|------------|--------------|----------|----------|--------------|--------------|----------|----------|
|                                 |            | p-value      | HR (95% CI) |          | HR (95% CI) |              |          |          |
| Age (yr)                        | 0.768      | 0.763 (0.127–4.591) |          |          |              |              |          |          |
| Estrogen receptor               | 0.680      | 0.964 (0.158–5.886) |          |          |              |              |          |          |
| Progesterone receptor           | 0.841      | 1.253 (0.138–11.410) |          |          |              |              |          |          |
| HER2                            | 0.331      | 0.646 (0.267–1.561) |          |          |              |              |          |          |
| miRNA let-7                     | 0.188      | 0.222 (0.024–2.080) |          |          |              |              |          |          |
| lncRNA H19                      | 0.124      | 0.174 (0.019–1.619) |          |          |              |              |          |          |
| Risk score                      | 0.029      | 0.126 (0.020–0.806) | 0.035    | 0.090 (0.010–0.844) |          |          |          |
| T stage                         | 0.379      | 1.638 (0.546–4.918) |          |          |              |              |          |          |
| N stage                         | 0.085      | 2.979 (0.861–10.305) |          |          |              |              |          |          |
| Stage                           | 0.104      | 2.648 (0.819–8.566) |          |          |              |              |          |          |
| Chemotherapy regimen (EC/EC-P)  | 0.477      | 0.447 (0.049–4.110) |          |          |              |              |          |          |
| Treatment response (CR+PR/PD+SD)| 0.048      | 0.107 (0.012–0.976) | 0.432    | 0.315 (0.018–5.607) |          |          |          |

HR = hazard ratio; CI = confidence interval; HER2 = human epidermal growth factor receptor 2; miRNA = microRNA; lncRNA = long non-coding RNA; EC = epirubicin and cyclophosphamide; EC-P = epirubicin, cyclophosphamide followed by paclitaxel; CR = complete response; PR = partial response; PD = progressive disease; SD = stable disease.

https://doi.org/10.4048/jbc.2018.21.2.142

http://ejbc.kr
Although randomized clinical trials have not shown significant differences in long-term outcomes regarding whether chemotherapy is administered before or after surgery, neoadjuvant chemotherapy improves surgical outcomes and provides important prognostic information on treatment responses [8,12]. Many gene-based qRT-PCR assays of RNA isolated from embedded breast cancer tissue samples can be used to predict prognoses, including survival, recurrence, or treatment responses. In our previous study, we reported that in primary breast cancer, low levels of let-7a were associated with chemotherapy resistance [10]. In this study, we focused on the combined prognostic value of let-7a and H19 expression. Consistent with basic research showing that the imprinted H19 gene may antagonize let-7a, we observed that H19 expression is negatively correlated with let-7a expression and that lower expression of let-7a and higher expression of H19 are associated with neoadjuvant chemotherapeutic resistance in breast cancer patients. In addition, paclitaxel-resistant breast cancer cell lines highly expressed H19, and knockdown of H19 expression restored their respective chemosensitivity. Furthermore, we developed a signature that could predict the survival of patients receiving neoadjuvant chemotherapy, and ROC analysis suggested that the signature has greater survival-predicting ability than H19 or let-7a expression alone.

The H19 gene is a highly conserved gene cluster that regulates embryonal development and growth [13]. In humans, H19 expression is strongly induced during embryogenesis and is downregulated after birth except in skeletal and heart muscle [14]. The overexpression of H19 in either tumor tissues or serum predicted poor prognosis among patients with colorectal cancer, non-small-cell lung cancer, gastric cancer, esophageal squamous cell carcinoma, or other malignancies [15-18]. However, let-7 miRNAs have been postulated to function as tumor suppressors by silencing RAS and HMGA2. Iorio et al. [19] reported that let-7 is rarely expressed in breast tumors compared with normal breast tissue based on microarray analysis. In addition, Kallen et al. [9] demonstrated that the conserved, imprinted H19 binds to let-7 and inhibits its function, thus acting as a molecular sponge. However, few clinical studies have explored the relationship between H19 and let-7a expression levels and their prognostic value, and it remains unknown whether H19 or let-7a levels could accurately predict the short- and long-term outcomes of primary breast cancer patients who receive neoadjuvant chemotherapy. Therefore, as far as we know, this is the first study to focus on this issue and construct a combined signature.

This study has some limitations that should be acknowledged. First, this was a retrospective single-center study. Thus, no independent cohorts were evaluated to prove the prognos-
tic value of this signature. Second, the optimal cutoff value for the combined signature demands external validation. Third, we analyzed only pretreatment biopsy specimens, and it remains unclear whether chemotherapy influences the expression of H19 and let-7a and whether dynamic changes in the combined signature can predict prognosis. Therefore, future prospective clinical trials and larger cohorts should emphasize and clarify the value of the combined signature, and further studies should include more homogeneous patients.

In summary, a risk score cutoff value of −0.1 was adopted to predict the short- and long-term outcomes of primary breast cancer patients who received neoadjuvant chemotherapy. Both the univariate and multivariate analyses showed that a risk score > −0.1 was related to poor treatment responses, OS, and PFS. TNM staging and HER2 tumor status partially contributed to an estimate of absolute benefits expected from systemic neoadjuvant chemotherapy, but the stratification was conducted primarily using anatomical and pathological information. Conversely, our signature could highlight the biological characteristics of breast cancer and provide unique information independent of TNM staging and HER2 status. In addition, measuring H19 and let-7a levels in patients using qRT-PCR might be a convenient and clinically available procedure. Furthermore, we observed that the combined signature had a higher AUC value than either H19 or let-7a expression alone. Thus, it is reasonable to conclude that the combined signature is a superior predictor of survival.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

ACKNOWLEDGMENTS

We would like to thank all the pathologists, oncologists, surgeons, and nurses who contributed to this study.

REFERENCES

1. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011;378:1461-84.
2. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007;18:1927-34.
3. Thum T, Condorelli G. Long noncoding RNAs and microRNAs in cardiovascular pathophysiology. Circ Res 2015;116:751-62.
4. Voortman J, Goto A, Mendouboure J, Sohn JJ, Shetter AJ, Saito M, et al. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 2010;70:4828-88.
5. He FC, Meng WW, Qu YH, Zhou MX, He J, Lv P, et al. Expression of circulating miRNA-20a and let-7a in esophageal squamous cell carcinoma. World J Gastroenterol 2015;21:4660-5.
6. Vennin C, Sprynt N, Dahmani E, Juliens S, Bertucci E, Finetti P, et al. H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Myb and Cbl-b. Oncotarget 2015;6:29209-23.
7. Si X, Zang R, Zhang E, Liu Y, Shi X, Zhang F, et al. LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. Oncotarget 2016;7:81452-62.
8. Peng F, Li TT, Wang KL, Xiao GQ, Wang JH, Zhao HD, et al. H19/let-7/ LIN28 reciprocal negative regulatory circuit promotes breast cancer stem cell maintenance. Cell Death Dis 2017;8:e2569.
9. Kallen AN, Zhou XB, Xu J, Qiao C, Ma Y, Yan L, et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell 2013;52:101-12.
10. Wu J, Li S, Jia W, Deng H, Chen K, Zhu L, et al. Reduced let-7a is associated with chemoresistance in primary breast cancer. PLoS One 2015;10:e0133643.
11. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-9.
12. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778-85.
13. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005;97:188-94.
14. Gabory A, Jammes H, Dandolo L. The H19 locus: role of an imprinted non-coding RNA in growth and development. Bioessays 2010;32:473-80.
15. Onyango P, Feinberg AP. A nucleolar protein, H19 opposite tumor suppressor (HOTS), is a tumor growth inhibitor encoded by a human imprinted H19 antisense transcript. Proc Natl Acad Sci U S A 2011;108:16759-64.
16. Li S, Hua Y, Jin J, Wang H, Du M, Zhu L, et al. Association of genetic variants in lncRNA H19 with risk of colorectal cancer in a Chinese population. Oncotarget 2016;7:25470-7.
17. Zhou X, Yin C, Dang Y, Ye F, Zhang G. Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. Sci Rep 2015;5:11516.
18. Zhang E, Li W, Yin D, De W, Zhu L, Sun S, et al. c-Myc-regulated long non-coding RNA H19 indicates a poor prognosis and affects cell proliferation in non-small-cell lung cancer. Tumour Biol 2016;37:4007-15.
19. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-70.